Shire Looks To Build Around Xiidra, Sanofi Faces Toujeo Challenge, Amgen Downplays Romosozumab Data
Shire, Sanofi and Amgen were among the companies presenting at the Bank of America Merrill Lynch Global Healthcare Conference Sept. 14-16 in London. Here are some key takeaways from those presentations.
You may also be interested in...
The full data for Sanofi/Regeneron's ODYSSEY ESCAPE study of their PCSK9 inhibitor Praluent confirm its use in reducing the need for expensive apheresis procedures in severe hypercholesterolemia patients, but the extent of the cost savings is still unclear.
Losing Medivation could end up being a winning proposition for the French pharma if it can boost its cancer franchise another way, like by acquiring its partner in multiple collaborations Regeneron or making a less expensive takeout, such as Incyte or Ariad.
Abaloparatide looks better for improving bone mass with less hypercalcemia than Lilly's first-in-class Forteo in the Phase III ACTIVE study, but it remains to be seen whether this will be enough to get ahead in the increasingly crowded osteoporosis market.